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Intrinsic Gene Expression Subsets of Diffuse
Cutaneous Systemic Sclerosis Are Stable in Serial
Skin Biopsies
Sarah A. Pendergrass1, Raphael Lemaire2, Ian P. Francis2, J. Matthew Mahoney1, Robert Lafyatis2 and
Michael L. Whitfield1
Skin biopsy gene expression was analyzed by DNA microarray from 13 diffuse cutaneous systemic sclerosis
(dSSc) patients enrolled in an open-label study of rituximab, 9 dSSc patients not treated with rituximab, and 9
healthy controls. These data recapitulate the patient ‘‘intrinsic’’ gene expression subsets described previously,
including fibroproliferative, inflammatory, and normal-like groups. Serial skin biopsies showed consistent and
non-progressing gene expression over time, and importantly, the patients in the inflammatory subset do not
move to the fibroproliferative subset, and vice versa. We were unable to detect significant differences in gene
expression before and after rituximab treatment, consistent with an apparent lack of clinical response. Serial
biopsies from each patient stayed within the same gene expression subset, regardless of treatment regimen or
the time point at which they were taken. Collectively, these data emphasize the heterogeneous nature of SSc
and demonstrate that the intrinsic subsets are an inherent, reproducible, and stable feature of the disease that is
independent of disease duration. Moreover, these data have fundamental importance for the future
development of personalized therapy for SSc; drugs targeting inflammation are likely to benefit those patients
with an inflammatory signature, whereas drugs targeting fibrosis are likely to benefit those with a fibro-
proliferative signature.
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INTRODUCTION
Systemic sclerosis (SSc) is a multisystem autoimmune
disorder with a hallmark of skin fibrosis and thickening along
with significant internal organ involvement (Mayes et al.,
2003). SSc has historically been divided into limited and
diffuse disease based on the extent of skin involvement, with
limited cutaneous SSc (lSSc) involving skin restricted to the
regions below the elbows, knees, and face, and diffuse
cutaneous SSc (dSSc), including more proximal skin. The
degree of skin involvement has a direct correlation with SSc
prognosis and internal organ complications (Barnett et al.,
1988; Scussel-Lonzetti et al., 2002). However, within dSSc
and lSSc, there is a heterogeneous range of skin and internal
organ involvement. Approaches that objectively quantify
disease heterogeneity and predict internal organ involvement
are critically needed.
Previous genome-wide gene expression studies in SSc skin
identified disease-specific gene expression signatures in both
lesional and non-lesional skin biopsies that are distinct from
those found in healthy controls (Whitfield et al., 2003;
Gardner et al., 2006; Milano et al., 2008). In addition, we
have shown that distinct gene expression signatures divide
SSc patients into ‘‘intrinsic subsets’’, capturing the clinical
heterogeneity of limited versus diffuse SSc, but extending this
heterogeneity by revealing that patients with dSSc fall into
several different subsets based on gene expression in the skin
(Milano et al., 2008). These results suggested that distinct
pathogenic mechanisms may drive disease in different
patients or at different stages of the disease. We previously
identified four intrinsic gene expression subsets: a ‘‘diffuse-
proliferation’’ group comprised completely of patients with
dSSc (here referred to as fibroproliferative), showing increased
expression of genes associated with cell proliferation that
could be further subdivided into two groups: ‘‘diffuse 1’’ and
‘‘diffuse 2’’; an ‘‘inflammatory’’ group comprised of dSSc,
lSSc, and morphea samples, showing increased expression
of genes associated with inflammation; a ‘‘limited’’ group
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comprised primarily of patients with lSSc; and the ‘‘normal-
like’’ group of dSSc and lSSc patients, showing gene
expression similar to healthy controls. A weak relationship
was found between disease duration and these intrinsic
subsets, suggesting that they might reflect evolution of the
disease process rather than biologically distinct pathogenic
processes.
Here we recapitulate the intrinsic subsets, show these
subsets are stable over time, and that treatment with ritu-
ximab fails to alter skin gene expression. These data illustrate
that patients with an inflammatory signature do not go on to
develop a fibroproliferative signature, suggesting a possible
explanation as to why, in the past, broad-spectrum anti-
inflammatory agents may not have worked in SSc. It also
indicates that different pathogenic mechanisms drive disease
pathogenesis within phenotypically similar patients with
dSSc and that this heterogeneity can be consistently and
reproducibly detected by analyzing skin gene expression,
having broad implications for the future development of
therapies for SSc.
RESULTS
dSSc skin biopsies can reproducibly be divided into ‘‘intrinsic’’
gene expression subsets
We analyzed skin biopsies from dSSc patients for gene
expression changes indicative of patient-specific heterogene-
ity. Gene expression was measured in 60 skin biopsies from
22 patients with dSSc and 9 healthy controls (Supplementary
Table 1 online). A total of 89 microarrays were hybridized,
which included 29 technical replicates. All patients were
biopsied at a lesional forearm site; a subset was also biopsied
at a non-lesional back site. Clinical data can be found in
Supplementary Table 2 online.
Skin biopsies from dSSc patients were analyzed before and
after treatment with rituximab for gene expression changes.
Consistent with the lack of clinical response (Lafyatis et al.,
2009), we did not find a significant change in gene expression
associated with rituximab treatment. Instead, gene expression
was nearly identical between serial biopsies of patients before
and after treatment (see Supplementary Material online;
Supplementary Data File S1 online; and Supplementary
Figure S2 online).
We previously selected a set of ‘‘intrinsic’’ genes that showed
consistent non-changing gene expression between the lesional
forearm and non-lesional back biopsies, but showed the largest
changes between different patients (Milano et al., 2008),
allowing us to compare differences between patients rather
than between lesional/non-lesional biopsies. This resulted in
the identification of patient subsets based on gene expression.
These groups were labeled fibroproliferative, inflammatory,
limited, and normal-like based on the biological gene expres-
sion programs that predominated in each subset. We used
the same strategy to classify patients in this independent
cohort of patients. Hierarchical clustering using 2,377
intrinsic genes (false discovery rate of 0.4%) recapitulated
the major intrinsic subsets, including the fibroproliferative
(diffuse 1 and diffuse 2), inflammatory, and normal-like
groups (Figures 1a and 2).
Patient biopsies taken at different time points show similar
patterns of gene expression
We carried out a second analysis to specifically explore whether
patients showed significant alterations in gene expression subset
over time (intrinsic-by-time point analysis). Genes were
selected that showed the most consistent expression at a
single time point for each patient, but had the most diverse
expression between time points (1,888 genes, false discovery
rate of 1.58%). Organizing the samples by hierarchical
clustering shows that serial biopsies from 13 of 14 patients
group together, even though this analysis emphasizes
differences between time points (Figure 1b and Supplemen-
tary Figure S1 online), indicating that serial biopsies are
more similar to each other than to any other samples over
the 6 months to 2 years analyzed. The dendrograms for the
intrinsic-by-time point and intrinsic-by-patient analyses are
remarkably similar, confirming that gene expression varies
little across time (Figure 1). (Additional analyses are available
in the Supplementary Material online.)
Distinct pathways are associated with each intrinsic gene
expression group
Distinct sets of genes were associated with each subset that
corresponded to specific biological processes in the skin,
represented by gene ontology (GO) biological processes
(Milano et al., 2008; Figure 2; and Supplementary Data file
S3 online). Genes associated with the inflammatory group are
enriched for the GO biological processes of immune system
response and inflammatory response (Pp0.001, The Data-
base for Annotation, Visualization, and Integrated Discovery
analysis (DAVID); Figure 2d and e) and include IFN-induced
genes, such IFIT1, IFIT2, and OAS3. This group of genes is
also enriched for the GO biological processes of vasculature
development (Pp0.01), including the genes vascular en-
dothelial growth factor C (VEGFC) and endoglin (ENG), as
well as genes associated with fibrosis (COL6A3, COL6A1,
COL5A2, COL5A1, COL1A1, and COL1A2), collagen oligo-
meric matrix protein (COMP), and matrix metalloproteinase
9 (MMP9) (Varga and Jimenez, 1995; Jimenez et al., 1996;
Ramirez et al., 2006; Liu and Zhang, 2008).
Two groups of dSSc patients showed increased expression
of the proliferation signature indicative of dividing cells
(Figure 2g) and low expression of the inflammatory signature
(Figure 2d), labeled diffuse 1 (blue) and diffuse 2 (red,
showing a more prominent proliferation signature) (Whitfield
et al., 2002). Genes associated with this subset are enriched
for the GO biological processes of mitosis, m-phase of the
mitotic cell cycle, chromosome segregation (Pp0.001), and
DNA metabolic process (Pp0.05). These include the cell
cycle regulators CDCA8, CDC2, the kinesins KIF2C, KIF11,
and cyclins CCNB2 and CCNB1.
Pathways more prominent in this study than seen pre-
viously include fatty acid metabolism (Milano et al., 2008),
with increased expression in the normal-like and diffuse 1
subsets (Figure 2c). Enriched GO biological processes included
lipid metabolism and fatty acid metabolism (Pp0.001),
which contained the peroxisome proliferation–activated
receptor-g (PPAR-g) coactivator a 1 gene. A group of genes
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with related function, but a different expression pattern,
centers on PPAR-g gene expression (Figure 2f) (Wei et al.,
2010). Genes within this PPAR-g pathway–related group
include several PPAR-g target genes: CD36 (Huang et al.,
2004), lipoprotein lipase (LPL) (Schoonjans et al., 1996),
stearoyl-CoA desaturase (SCD) (Vondrichova et al., 2007),
and catalase (CAT) (Girnun et al., 2002).
We summarized the differentially regulated biological path-
ways by averaging the genes associated with each (Supplemen-
tary Material online and Supplementary Figures S3–S4 online).
We observe an increase in pathways associated with immune
system activation (Supplementary Figure S3a online) and an
increase in gene expression associated with B cells, CD8þ T
cells, leukocytes, macrophages, and IFN-treated keratino-
cytes and fibroblasts (Supplementary Figure S3b online). The
diffuse 2 subset showed an increase in cell cycle–related
processes, decreases in cholesterol, steroid and fatty acid
metabolism, as well as enrichment of genes associated with
activated peripheral blood mononuclear cells, TNF-a-treated
keratinocytes, T cells, and dendritic cells (Supplementary
Figure S3a and b online). The normal-like and diffuse 1 group
showed a decrease in immune activation and increases in
lipid metabolism.
Intrinsic gene expression groups are stable over time
Two results from this study suggest that the intrinsic subsets
are not dependent on disease duration. The four major intrinsic
subsets identified in our previous study, where individuals
had variable and longer disease duration (Milano et al.,
2008), were also found in this study cohort where all patients
have early-stage disease (Supplementary Figure S5a online). If
the subsets were dependent on disease duration, then we
would expect a skewing toward the early subset in these data.
In addition, there is no significant difference in disease
duration between subsets measured here (Supplementary
Figure S5b online). Collectively, these findings indicate that
gene expression subsets are an inherent feature of the clinical
dSSc phenotype and that this feature is independent of
disease duration.
Despite the consistent gene expression, modified Rodnan
skin score (MRSS) did change in patients who provide long-
itudinal biopsies (Supplementary Figure S6 online). In all, 7 of
the 15 patients showed increases in skin score, 2 patients
(RIT7 and RIT14) showed a decrease and the remaining 6
showed little change. In all cases, patients maintained a
stable pattern of gene expression. The range of MRSS for
patients in this data set has a slightly broader distribution than
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Figure 1. Gene expression over time in systemic sclerosis (SSc) skin. Shown are the hierarchical clustering dendrograms of the (a) ‘‘intrinsic-by-patient’’ and
(b) ‘‘intrinsic-by-time point’’ analyses. Dendrogram branches are colored by subtype: normal-like (green), inflammatory (purple), diffuse 1 (blue), and diffuse 2
(red), which represent the fibroproliferative group. Statistically significant branches are indicated by an asterisk. Black bars below the sample identifiers indicate
arrays from skin biopsies from the same patient that clustered together; yellow bars below the identifiers identify arrays for a single patient that split between
groups. Black arrows connect longitudinal samples. Overlaid between the two dendrograms are shaded bars indicating arrays that changed intrinsic subset
between the two analyses. dSSc, diffuse cutaneous systemic sclerosis; RIT, samples in the rituximab study.
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IFITM2 Interferon induced transmembrane protein 2
TIMP1 Tissue inhibitor of metalloproteinase 1
LGALS9 Lectin, galactoside-binding, soluble, 9
IRF7 Interferon-regulatory factor 7
STAT1 Signal transducer and acivator of transcription 1
TAP1 Transporter 1
CXCL1 Chemokine ligand 1
TRAF5 TNF receptor-associated factor 5
PRKCA Protein kinase C, alpha
HLA-DPB1 Major histocompatibility complex, class II, DP beta 1
IL27RA Interleukin-27 receptor, alpha
LTB Lymphotoxin beta (TNF superfamily, member 3)
PTX3 Pentaxin-related gene, rapidly induced by IL-1 beta
VEGFC Vascular endothelial growth factor C
TNFRSF12A Tumor necrosis factor receptor family, member 12A
COMP Cartilage oligomeric matrix protein
MMP9 Matrix metalloproteinase 9
COL4A1 Collagen, type IV, alpha 1
C3 Complement component 3
NRP1 Neuropilin 1
COL5A1 Collagen, type V, alpha 1
COL6A3 Collagen, type VI, alpha 3
FAP Fibroblast activation protein, alpha
CTGF Connective tissue growth factor
CTHRC1 Collagen triple helix repeat containing 1
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IL4R Interleukin-4 receptor
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PDK4 Pyruvate dehydrogenase kinase, isoenzyme 4
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CDC20 CDC20 cell division cycle 20 homolog
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the skin scores in Milano et al. (2008) (Supplementary Figure
S5c online). When lSSc patients are excluded, the MRSS of
proliferative and inflammatory groups though broader in
distributions are otherwise similar to our past study (Milano
et al., 2008) (Supplementary Figure S5c and d online). The
inflammatory group has the widest range of MRSS scores,
whereas the normal-like group consistently shows lower MRSS
scores in both data sets. Autoantibodies did not show a
significant association with intrinsic subset (Supplementary
Tables S2 online). One diffuse 1 patient was anti-scl-70
positive (1/4; P¼0.52, Fisher’s exact test), two inflammatory
patients were anti-RNA polymerase III positive (2/7;
P¼0.12), and three unclassified patients were anti-scl-70
positive (2/3; P¼0.051) and anti-centromere positive (1/3;
P¼0.16). Diffuse 2 patients were negative for all three
measured autoantibodies (P¼ 0.52).
Independent validation by immunohistochemistry
To validate the mRNA expression, we analyzed proteins for
COMP and IFN-induced transmembrane protein 3 (IFITM3)
in representative biopsies spanning the intrinsic subsets.
Both showed highest expression in the inflammatory subset
consistent with gene expression data (Figure 2d and
Supplementary Figure S7 online). Immunohistochemical
staining results paralleled and confirmed the gene expression
findings. COMP showed highest expression in the inflamma-
tory subset and lowest in the diffuse 2 subset (Po0.05), with
slightly higher expression in the diffuse 1 subset (Supple-
mentary Figure S7a online); protein staining was most
prevalent in dermal fibroblasts of SSc patients of the
inflammatory subset (Supplementary Figure S7c and g
online), while absent in controls (Supplementary Figure S7e
online). IFITM3 showed highest expression in both the
inflammatory and diffuse 2 subsets (Supplementary Figure
S7b online) and lowest expression in the diffuse 1 subset
(Po0.05), with staining around the microvasculature in the
skin (Supplementary Figure S7d and h online). These data
confirm and extend the gene expression findings at the
protein level.
Validation of the 995-gene intrinsic subset gene set
We next determined whether the 995 genes selected in our
previous study could stratify the cohort of patients described
here into the intrinsic subsets (Milano et al., 2008), and thus
could be developed into a classifier for subset stratification. In
total, 808 genes that passed basic quality filters were used to
organize the samples by hierarchical clustering (Figure 3b),
showing that 26 out of 31 dSSc skin biopsies from different
anatomical sites or time points were grouped together by
patient (Figure 3a). The subsets identified previously are
similar to those found here using the same set of genes
(Milano et al., 2008; Figure 3c). The fibroproliferative and
inflammatory groups in the two data sets are indicated with
the fibroproliferative groups in red and the inflammatory
group in purple. Subsets of overlapping genes between the
groups are indicated. The inflammatory signature is more
prominent in the data set presented here, whereas the
proliferation signature is more prominent in our previous
report (Milano et al., 2008). Therefore, the original 995 genes
can stratify an independent cohort into the intrinsic patient
subsets.
Surrogate gene biomarkers of MRSS
We previously reported a 177-gene expression signature that
could serve as surrogate biomarker of MRSS (Milano et al.,
2008). We refined this by identifying 44 genes that were
present in the 177-gene signature, and also found in the
intrinsic-by-patient analysis of this study (Figure 2). Organiz-
ing the samples using these 44 genes revealed two major
subdivisions of samples. One included both dSSc patients
and healthy controls (Figure 4a, group 1), whereas the other
included only dSSc patients (Figure 4a, group 2). Subjects
in these groups showed a significant difference in mean
MRSS (group 1: mean 17.92, standard deviation 11.61;
group 2: mean 25.90, standard deviation 8.52; t-test,
P¼ 0.005; Figure 4b).
Gene expression gradients are evident within a gene
expression subset
To further power the analysis of SSc skin gene expression
across time scales that cannot be easily captured with
longitudinal biopsies, we combined the gene expression
analyses from both this and our previous study (Milano et al.,
2008). The combined data set includes skin biopsies from 39
patients with dSSc, 7 with lSSc, 3 with morphea, 1 patient
with eosinophilic fasciitis, and skin biopsies from 15 healthy
control subjects, totaling 121 biopsies. After distance-weighted
discrimination adjustment to remove systematic differences
(Benito et al., 2004), intrinsic analysis was performed, 3,551
probes selected (false discovery rate of 0.07%; Figure 5a),
and the combined data sets clustered hierarchically. The two
data sets recapitulated the major intrinsic subsets (Figure 5a).
Gene expression in the ‘‘fibroproliferative’’ and ‘‘inflamma-
tory’’ groups both showed gradients of gene expression
within their respective groups (Figure 5a). In the proliferation
group, the dendrogram split samples with high expression of
the signature (‘‘Prolif 1’’) and low expression (‘‘Prolif 2’’).
Similarly, the inflammatory group contained samples with
high (‘‘Inflam 1’’) and low (‘‘Inflam 2’’) expression of the
signature. To determine if the intensity of these signatures
Figure 2. Recapitulation of the intrinsic subsets. In all, 2,377 genes were selected from 89 arrays (31 individuals) by ‘‘intrinsic-by-patient’’ analysis.
(a) Hierarchical clustering dendrogram shows the normal-like (green branches), inflammatory (purple), and fibroproliferative groups (diffuse 1 (blue), and
diffuse 2 (red)). Significance of clustering was determined by Statistical Significance of Clustering (SigClust). Healthy control identifiers are green and diffuse
cutaneous systemic sclerosis (dSSc) are black. RIT indicates samples in the rituximab study. Black bars indicate patient samples that clustered together;
the yellow bar indicates arrays from patient RIT3 that did not cluster together. (b) Heat map of genes and samples clustered hierarchically. (c) Fatty acid synthesis
genes. (d and e) Inflammatory and collagen genes. (f) Peroxisome proliferation–activated receptor-g (PPAR-g) genes. (g) Proliferation cluster genes.
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were associated with disease duration or MRSS, we
compared the distributions between these two parameters
within each group (Figure 6). The ‘‘Prolif 1’’ group had a
significantly longer disease duration (t-test, P¼0.0027)
compared with ‘‘Prolif 2’’ and a trend towards a higher
MRSS (Po0.05). In contrast, the ‘‘Inflam 2’’ group, which had
a higher inflammatory gene expression signature, showed a
significantly higher average MRSS (t-test, P¼0.016), with
40
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FBLN1 Fibulin 1
PDGFRL Platelet-derived growth factor receptor-like
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CDC7 CDC7 cell division cycle 7
CENPE Centromere protein E, 312 kDa
LGALS8 Lectin, galactoside-binding, soluble, 8 (galectin 8)
TNFRSF12A Tumor necrosis factor receptor superfamily, member 12A
TMOD3 Tropomodulin 3 (ubiquitous)
CRTAP Cartilage associated protein
CFHL1 Complement factor H-related 1
NR3C1 Nuclear receptor subfamily 3, group C, member 1
PCOLCE2 Procollagen C-endopeptidase enhancer 2
IGFBP5 Insulin-like growth factor binding protein 5
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ECM2 Extracellular matrix protein 2, female organ and adipocyte specific
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Figure 4. Surrogate gene expression biomarkers of modified Rodnan skin score (MRSS). (a) Probes that matched the 177 genes with correlations above |0.5|
from Milano et al. (2008) were extracted from the ‘‘by-patient’’ intrinsic analysis, resulting in 44 genes. Hierarchical clustering results in two groups. Group 1
(red branches) includes dSSc and healthy control skin biopsies, whereas group 2 (black branches) includes primarily dSSc skin biopsies. The first row of bars
below the dendrogram indicates the intrinsic subset assignment in the ‘‘by-patient’’ analysis (normal-like, green; diffuse 1, blue; diffuse 2, red; inflammatory,
purple; unclassified, black). The second row of bars indicates sample diagnosis, dSSc (red) or healthy control (black). (b) Box plot comparison of MRSS between
the two groups shows a statistically significant difference in MRSS (two-sample t-test, P¼ 0.005). The MRSS at time of biopsy is plotted with open circles.
Figure 3. Concordance between data sets. Hierarchical clustering of 808 genes that matched the 995 intrinsic genes from Milano et al. (2008) (187 did not
pass the basic filtering criteria). (a) Hierarchical clustering dendrogram shows normal-like (green), inflammatory (purple), diffuse-proliferation (diffuse 1
(blue) and diffuse 2 (red)), and limited groups (yellow). Significant branches are indicated by asterisk. Black bars indicate subject samples that clustered together.
(b) Heat map for the 808 genes. (c) Heat map of the original 995 ‘‘intrinsic’’ genes in Milano et al. (2008). The fibroproliferative groups that are between
the two data sets are connected in red and the inflammatory groups connected in purple; genes found in the respective clusters of both data sets are
indicated. dSSc, diffuse cutaneous systemic sclerosis; RIT, samples in the rituximab study.
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little difference in disease duration across the subgrouping.
Thus, this analysis suggests that the gene expression within
a group changes intensity with increased disease severity
and/or duration.
DISCUSSION
SSc is a progressive disease, with skin going through various
phases that can begin with edema, then progressive fibrosis,
and in some cases a skin softening late in the disease. Past
studies have suggested that SSc skin pathology evolves from
inflammatory to fibrotic changes over time (Fleischmajer
et al., 1977, 1978; Roumm et al., 1984; Kraling et al., 1995).
Our molecular analyses suggest that inflammatory changes in
the skin are not part of an evolving process, leading to
fibrosis, but rather represent a subset of patients, with other
patients having significantly less skin inflammation as part of
the pathological process. The data presented here indicate
that the gene expression subsets are stable over time. We
show that measuring gene expression of skin biopsies from
patients at different time points consistently classifies the
patients into the same intrinsic subsets. In addition, these data
taken from a cohort of patients with shorter disease duration
compared with our previous studies of patients with longer
disease duration show the same disease subsets.
Strikingly, although patients do not appear to move between
subsets over time, patients within inflammatory and particularly
fibroproliferative subsets show changes in the intensity of the
signature associated with disease duration. Similar changes in
intensity of gene expression was found in a study of limited
SSc patients with and without PAH, suggesting that as disease
1.
00
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6
0
Above Median Below
–
0.
6
–
1.
00
Proliferative Inflammatory Lim Normal - like
Inflam 1 Inflam 2Prolif 1 Prolif 2
e
Figure 5. Consistent classification and expression gradients within subsets. Data from this study and from Milano et al. (2008) were merged to create a single
data set of 164 arrays. In all, 3,551 intrinsic genes were selected (false discovery rate of 0.07%). (a) Heat map of 2D hierarchical clustering. (b) Clustering
dendrogram with branches indicating the intrinsic subset each sample was assigned in the independent data set analyses (proliferative (red), inflammatory
(purple), limited (yellow), and normal-like (green)). The first row of bars below the dendrogram indicates patient diagnosis (dSSc, red; limited cutaneous SSc
(lSSc), yellow; morphea and eosinophilic fasciitis, blue; healthy controls, green). The second row of bars indicates the data set the samples were obtained:
Milano et al., red; this study, black. (c) Inflammatory gene cluster. (d) Proliferation gene cluster. (e) Fatty acid synthesis gene cluster.
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becomes more severe, the intensity of the changes increases
(Pendergrass et al., 2010). Our data are consistent with
previous observations that the expression of pro-fibrotic
genes in non-lesional SSc fibroblasts tends to be intermediate
between that observed in healthy and lesional SSc fibroblasts
(Chen et al., 2005). Thus, our data suggest that different
biological processes may underpin dSSc pathogenesis in dif-
ferent patient subsets, and that the intensity of these processes
change over time. Although we cannot exclude the possibility
that analysis of serial biopsies over a longer period of time
would show patients changing subsets, the data here support
the notion that a patient could be assigned to a specific
intrinsic subset early in their disease course. These observa-
tions then have the potential of suggesting treatments that
block the immune response if a patient displays an inflam-
matory signature, or treatments that block fibrosis, if they
posses a fibroproliferative signature. Thus, as the pathogenic
mechanisms underlying intrinsic subsets are identified, patient
subset identification might permit specific targeting of patho-
genic processes. A TGFb-responsive signature appears to
drive at least in part pathogenesis in the fibroproliferative
subset of patients (Sargent et al., 2009), emphasizing the
contribution of this cytokine to the phenotype of SSc (Leask,
2009; Varga and Pasche, 2009), while IL-13 appears to play
an important role in the inflammatory subset (Greenblatt
et al., 2012).
This data set recapitulates and validates our originally
defined inflammatory, diffuse-proliferation, and normal-like
subsets of SSc patients. The disease duration of the cohort
analyzed here (o2 years) is more homogeneous and more
typical of when the disease is most actively progressing
compared with our previous report. Despite these differences,
the results show reproducibility of patient subsets in a com-
pletely new patient population from a different clinical center.
The reproducibility and stability of these gene expression-based
subsets confirms that they reflect fundamental underlying
pathogenic processes that differ between patients in the
different subsets, rather than stages in the progressive disease.
The addition of more serial biopsies covering a larger span of
time, coupled with longitudinal clinical data, should provide
prognostic information for patients in each group.
A subset of patients in this analysis was treated with
rituximab, a mAb that depletes mature B cells. In that open-
label trial of rituximab, patients did not show a significant
change in skin score, pulmonary function, or other measures
of organ involvement, although immunohistochemistry showed
depletion of both peripheral and skin-resident B cells (Lafyatis
et al., 2009). Several other unblinded clinical trials have
suggested some potential beneficial effect of rituximab on
skin and/or lung disease in patients with SSc (Wesson et al.,
2008; Bosello et al., 2010; Daoussis et al., 2010; Smith et al.,
2010). Rituximab may prove to have value in SSc, and it is
particularly intriguing to consider its potential efficacy in SSc-
associated interstitial lung disease where B cell infiltration is
often quite prominent (Lafyatis et al., 2007). However, our
studies here are consistent with our clinical trial results,
suggesting no or modest effect on skin disease. We therefore
believe that rituximab is more likely to show efficacy for SSc-
associated interstitial lung disease and that lung disease
would be a better target for a large-scale trial of B cell
depletion.
Comparing the results of Chung et al. (2009), who reported
two patients with dSSc that showed a response to treatment
with imatinib mesylate (Chung et al., 2009), with the results
reported here in rituximab-treated patients suggests that when
a clinical response is evident, one is also likely to find a gene
expression response. Thus, gene expression may be useful as
a surrogate outcome measure and for stratifying likely patient
responders in clinical trials. As the patients with an inflam-
matory signature do not go on to display a fibroproliferative
signature, and vice versa, it is essential to target patients with
a therapy that is appropriate to their gene expression
signature. Therefore, it will be imperative to identify patient
subsets in clinical trials as drugs may target only those in a
single subset.
MATERIALS AND METHODS
Patient selection, biopsy processing, and microarray
hybridization
All study participants gave written, informed consent under Boston
University Medical Center Institutional Review Board, an approved
protocol. The study conformed to Declaration of Helsinki principles.
Forearm lesional skin and, for a subset of patients, non-lesional back
skin were collected by punch biopsies (3–6mm) from 13 patients
enrolled in the rituximab study (Lafyatis et al., 2009), as well as from
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Figure 6. Association between disease duration and modified Rodnan skin
score (MRSS) within the proliferation and inflammatory subsets. Above the
dendrogram in Figure 5, the ‘‘Prolif 1’’, ‘‘Prolif 2’’, ‘‘Inflam 1’’, and ‘‘Inflam 2’’
groups are indicated. These are groups showing differences in the intensity
of gene expression within the proliferative and inflammatory subsets.
Box plots show differences in disease duration and MRSS between (a and b)
‘‘Prolif 1’’ and ‘‘Prolif 2’’, as well as between (c and d) ‘‘Inflam 1’’ and
‘‘Inflam 2’’ are apparent. Disease duration (months) is plotted for each
blopsy at time collection (a and c). MRSS is plotted for each blopsy in
panels b and d.
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9 additional patients with early dSSc (o1.5 years from diagnosis).
A total of 60 skin biopsies were collected from 22 patients with dSSc
and 9 healthy controls (Supplementary Tables S1 and S2 online).
RNA purification and microarray hybridization was carried out
essentially as described (Milano et al., 2008). Detailed methodology
is provided in Supplementary Text online.
Bioinformatic and statistical analyses
Intrinsic gene analysis was carried out as described previously
(Supplementary Material online; Milano et al., 2008). Gene expression
data were organized by average linkage hierarchically clustering
using Cluster 3.0 (http://bonsai.hgc.jp/~mdehoon/software/cluster/
software.htm) and visualized using Java TreeView (http://jtreeview.
sourceforge.net/). Significance of clustering was determined by
Statistical Significance of Clustering (Liu et al., 2008). Enriched GO
biological processes were determined using The Database for
Annotation, Visualization, and Integrated Discovery (Huang da
et al., 2007) (Supplementary Data File S5 online). Module maps
were created with Genomica. Correlation between gene expression
and clinical parameters were calculated using MATLAB (Mathworks,
Natick, MA). Statistics were carried out using R (http://www.
r-project.org/). Distance-weighted discrimination, utilizied the java
implementation (Benito et al., 2004). Gene expression data from this
study is available from NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/;
accession number GSE32413).
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